TMED7

Across TCGA pan-cancer cohorts, TMED7 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated TMED7 data layer compared with 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMED7 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated TMED7 expression acts as an unfavorable survival marker, although some lineages such as KIRC and COAD show a favorable association.

HNSC, KIRC, and UVM are the cancer types where TMED7 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.582	0.824	<.001	65	view →
KIRC	OS	Median	All	0.711	0.542	<.001	60	view →
UVM	DFS	Tertile	III,IV	0.240	0.854	.001	51	view →
CESC	DFS	Median	II,III,IV	0.305	0.647	.015	32	view →
LGG	OS	Median	All	0.857	0.932	<.001	30	view →
ESCA	DFS	Median	IV	0.205	0.634	.006	28	view →
SCLC	OS	Median	II,III,IV	0.563	0.814	.014	23	view →
PAAD	OS	Median	All	0.335	0.615	.001	22	view →
COAD	OS	Tertile	All	0.885	0.761	.009	19	view →
PRAD	DFS	Quartile	All	0.956	0.829	<.001	18	view →
LIHC	DFS	Quartile	All	0.463	0.636	.004	17	view →
BLCA	DFS	Quartile	All	0.250	0.581	.009	14	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

TMED7–HNSC (OS)

Open the HNSC breakdown →